Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors

Abstract

This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C 9-10 heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C 17 alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

1. A compound selected from compounds of the following formula and pharmaceutically acceptable salts thereof: 
       
         
           
           
               
               
           
         
         wherein: 
         A is an unsubstituted or substituted quinoline; 
         Q is independently a saturated or unsaturated C 1-7  alkylene group having a backbone length of 4 or less; 
         wherein backbone atoms of Q, which link A and —C(═O)NHOH, are denoted α, β, γ, and δ, starting with the backbone atom adjacent to —C(═O)NHOH; 
         wherein Q is unsubstituted or substituted with one or more substituents independently selected from —CONH 2 ,—CONMe 2 , —C(═O)Me, —F, —Cl, —Br, —I, —NO 2 , —OH, —OMe, —OEt, —O(iPr), —NH 2 , —NMe 2 , —NEt 2 , morpholino, —NHCOMe, -Ph, ═O, ═NH, ═NMe, and ═NOH; 
         with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position. 
       
     
     
       2. A compound according to  claim 1 , wherein A is quinolin-2-yl; quinolin-3-yl; quinolin-4-yl; quinolin-5-yl; quinolin-6-yl; or quinolin-7-yl; quinolin-8-yl; and is unsubstituted or substituted. 
     
     
       3. A compound according to  claim 2 , wherein A is:
 unsubstituted; or 
 substituted with one or more substituents independently selected from carboxylic acid; ester; amido; acyl; halo; cyano; nitro; hydroxy; ether; thiol; thioether; acyloxy; amino; acylamino; aminoacylamino; sulfonamino; sulfonyl; sulfonate; sulfonamido; C 5-20  aryl-C 1-7 alkyl; C 5-20 aryl; C 3-20 heterocyclyl; C 1-7 alkyl; oxo; imino; and hydroxyimino. 
 
     
     
       4. A compound according to  claim 2 , wherein A is:
 unsubstituted; or 
 substituted with one or more substituents independently selected from —C(═O)OMe, —C(═O)O(Pr), —C(═O)NHMe, —C(═O)Et, —C(═O)Ph, —F, —Cl, —NO 2,  —OMe, —OEt, —OPh, —OCH 2 CH 2 OH, —O—CH 2 -Ph, —NMe 2 , —SO 2 Me, —SO 2 Me 2,  —CH 2 -Ph, -Ph,-PhF, -Ph- Cl, —Me, -Et, -nPr, iPr, —CF 3 , —CH 2 CH 2 OH, and —CH 2 CH 2 NMe 2 . 
 
     
     
       5. A compound according to  claim 2 , wherein A is:
 unsubstituted; or 
 substituted with one or more substituents independently selected from —F, —Cl, —OMe, —OEt, —OPh, —O—CH 2 -Ph, —CH 2 -Ph, -Ph —Me, and -Et. 
 
     
     
       6. A compound according to  claim 2 , wherein A is unsubstituted. 
     
     
       7. A compound according to  claim 2 , wherein Q is independently an unsubstituted or substituted, saturated C 1-7 alkylene group; and has a backbone length of 4 or less. 
     
     
       8. A compound according to  claim 2 , wherein Q is independently an unsubstituted or substituted, unsaturated C 2-7 alkylene group; and has a backbone length of 4 or less. 
     
     
       9. A compound according to  claim 2 , wherein Q is independently an unsubstituted or substituted, saturated aliphatic C 1-7 alkylene group; and has a backbone length of 4 or less. 
     
     
       10. A compound according to  claim 2 , wherein Q is independently an unsubstituted or substituted, unsaturated aliphatic C 2-7 alkylene group; and has a backbone length of 4 or less. 
     
     
       11. A compound according to  claim 2 , wherein Q has a backbone length of from 2 to 4 atoms. 
     
     
       12. A compound according to  claim 2 , wherein Q has a backbone length of from 2 to 3 atoms. 
     
     
       13. A compound according to  claim 2 , wherein Q has a backbone length of 2 atoms. 
     
     
       14. A compound according to  claim 2 , wherein Q is unsubstituted at the α-position. 
     
     
       15. A compound according to  claim 2 , wherein Q is unsubstituted at the α-position and the β-position. 
     
     
       16. A compound according to  claim 2 , wherein Q is unsubstituted. 
     
     
       17. A compound according to  claim 2 , wherein Q is —CH═CH—, —CH 2 —CH 2 —, —CH(CH 3 )—CH 2 —, or —CH 2 —CH(CH 3 )—. 
     
     
       18. A compound according to  claim 2 , wherein Q is —CH═CH— or —CH 2 —CH 2 —. 
     
     
       19. A compound according to  claim 2 , wherein Q is —CH═CH—. 
     
     
       20. A compound according to  claim 2 , wherein Q is —CH 2 —CH 2 —. 
     
     
       21. A pharmaceutical composition comprising a compound as defined in  claim 1  and a pharmaceutically acceptable carrier. 
     
     
       22. A compound according to  claim 2 , selected from the following compounds, and pharmaceutically acceptable salts thereof: 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
       
     
     
       23. A pharmaceutical composition comprising a compound as defined in  claim 2  and a pharmaceutically acceptable carrier. 
     
     
       24. A method of inhibiting HDAC in a cell comprising contacting said cell with an effective amount of a compound as defined in  claim 2 . 
     
     
       25. A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound as defined in  claim 2 . 
     
     
       26. A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound as defined in  claim 2 . 
     
     
       27. A method for the treatment of an inflammatory disease comprising administering to a subject suffering from an inflammatory disease a therapeutically-effective amount of a compound as defined in  claim 2 . 
     
     
       28. A compound selected from compounds of the following formula and pharmaceutically acceptable salts thereof: 
       
         
           
           
               
               
           
         
         wherein: 
         A is independently quinolin-2-yl; quinolin-3-yl; quinolin-4-yl; quinolin-5-yl; quinolin-6-yl; quinolin-7-yl; or quinolin-8-yl; and is unsubstituted or substituted with one or more substituents independently selected from —C(═O)OMe, —C(═O)O(Pr), —C(═O)NHMe, —C(═O)Et, —C(═O)Ph, —F, —Cl, —NO 2 , —OMe, —OEt, —OPh, —OCH 2 CH 2 OH, —O—CH 2 -Ph, —NMe 2 , —SO 2 Me, —SO 2 Me 2 , —CH 2 -Ph, -Ph, -Ph-F, -Ph-Cl, -Me, -Et, -nPr, -iPr, —CF 3 , —CH 2 CH 2 OH, and NH 2 CH 2 NMe 2 ; and 
         Q is independently —CH ═CH— or —CH 2 —CH 2 —. 
       
     
     
       29. A compound according to  claim 28 , wherein A is independently quinolin-2-yl; quinolin-3-yl; quinolin-4-yl; quinolin-5-yl; quinolin-6-yl; quinolin-7-yl; or quinolin-8-yl; and is unsubstituted or substituted with one or more substituents independently selected from —F, —Cl, —OMe, —OEt, —OPh, —O—CH 2 -Ph, —CH 2 -Ph, -Ph, -Me, and -Et. 
     
     
       30. A compound according to  claim 28 , wherein Q is independently —CH═CH—. 
     
     
       31. A compound according to  claim 29 , wherein Q is independently —CH═CH—. 
     
     
       32. A compound according to  claim 28 , wherein Q is independently —CH 2 —CH 2 —. 
     
     
       33. A compound according to  claim 29 , wherein Q is independently —CH 2 —CH 2 —. 
     
     
       34. A pharmaceutical composition comprising a compound as defined in  claim 28  and a pharmaceutically acceptable carrier. 
     
     
       35. A method inhibiting HDAC in a cell comprising contacting said cell with an effective amount of a compound as defined in  claim 28 . 
     
     
       36. A method for the treatment of a proliferative condition comprising administering to a subject suffering from a proliferative condition a therapeutically-effective amount of a compound as defined in  claim 28 . 
     
     
       37. A method for the treatment of cancer comprising administering to a subject suffering from cancer a therapeutically-effective amount of a compound as defined in  claim 28 . 
     
     
       38. A method for the treatment of an inflammatory disease comprising administering to a subject suffering from an inflammatory disease a therapeutically-effective amount of a compound as defined in  claim 28 .